AstraZeneca (LON:AZN) Earns “Outperform” Rating from Credit Suisse Group
Credit Suisse Group reissued their outperform rating on shares of AstraZeneca (LON:AZN) in a research note published on Wednesday, ThisIsMoney.Co.Uk reports.
Other research analysts have also issued research reports about the stock. Goldman Sachs Group set a GBX 6,000 ($73.84) price target on shares of AstraZeneca and gave the stock a sell rating in a report on Tuesday, July 28th. Kepler Capital Markets restated a buy rating and set a GBX 9,200 ($113.22) price target on shares of AstraZeneca in a report on Tuesday, June 9th. Morgan Stanley restated an equal weight rating and set a GBX 9,000 ($110.76) price target on shares of AstraZeneca in a report on Tuesday, July 21st. Liberum Capital restated a buy rating on shares of AstraZeneca in a report on Friday, May 29th. Finally, Shore Capital restated a buy rating on shares of AstraZeneca in a report on Monday, July 27th. Six research analysts have rated the stock with a sell rating, two have issued a hold rating and twelve have assigned a buy rating to the stock. The company has a consensus rating of Hold and an average price target of GBX 8,347.78 ($102.73).
Shares of LON AZN opened at GBX 8,530 ($104.97) on Wednesday. The company has a 50 day simple moving average of GBX 8,583.32 and a 200 day simple moving average of GBX 7,938.56. The firm has a market cap of $111.94 billion and a PE ratio of 73.73. AstraZeneca has a 1 year low of GBX 83.80 ($1.03) and a 1 year high of GBX 9,537.09 ($117.37). The company has a debt-to-equity ratio of 171.72, a current ratio of 0.75 and a quick ratio of 0.56.
AstraZeneca Company Profile
AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.
Read More: Price Target
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.